Other Information
−Removed: During the period from April 1, 2025 to June 30, 2025, our officers (as defined in Rule 16a-1(f) under the Exchange Act) and/or directors adopted or terminated contracts, instructions or written plans for the purchase or sale of our securities as noted below:
+Added: During the period from July 1, 2025 to September 30, 2025, our officers (as defined in Rule 16a-1(f) under the Exchange Act) and/or directors adopted or terminated contracts, instructions or written plans for the purchase or sale of our securities as noted below:
Name and Title Action Date Trading Arrangement Total Shares Authorized
1 unchanged sentence
Rule 10b5-1* Non-Rule 10b5-1**
+Added: William Rastetter
18,000 5/19/2026
−Removed: Chief Executive Officer
−Removed: Matthew Abernethy
+Added: George Morrow
8/26/2025 X 15,000 5/19/2026
−Removed: Chief Financial Officer
−Removed: Darin Lippoldt
+Added: Eric Benevich
8/28/2025 X 12,830 2/4/2026
−Removed: Chief Legal Officer
+Added: Chief Commercial Officer
+Added: 9/3/2025 X 15,000 5/19/2026
+Added: Leslie Norwalk
+Added: 9/12/2025 X 15,000 9/12/2026
______________
16 unchanged sentences
Incorporated by reference to the Company’s Registration Statement on Form S-1 (Registration No.
−Removed: Neurocrine Biosciences, Inc.
−Removed: 2025 Equity Incentive Plan
−Removed: Incorporated by reference to Exhibit 99.2 of the Company’s Registration Statement on Form S-8 (Registration No.
−Removed: Form of Standard Stock Option Grant Notice and Option Agreement for use under the Neurocrine Biosciences, Inc.
−Removed: 2025 Equity Incentive Plan
−Removed: Incorporated by reference to Exhibit 99.3 of the Company’s Registration Statement on Form S-8 (Registration No.
−Removed: Form of Standard Restricted Stock Unit Award Grant Notice and Restricted Stock Unit Award Agreement for use under the Neurocrine Biosciences, Inc.
−Removed: 2025 Equity Incentive Plan
−Removed: Incorporated by reference to Exhibit 99.4 of the Company’s Registration Statement on Form S-8 (Registration No.
−Removed: Form of Director Stock Option Grant Notice and Option Agreement for use under the Neurocrine Biosciences, Inc.
−Removed: 2025 Equity Incentive Plan
−Removed: Incorporated by reference to Exhibit 99.5 of the Company’s Registration Statement on Form S-8 (Registration No.
−Removed: Form of Director Restricted Stock Unit Award Grant Notice and Restricted Stock Unit Award Agreement for use under the Neurocrine Biosciences, Inc.
−Removed: 2025 Equity Incentive Plan
−Removed: Incorporated by reference to Exhibit 99.6 of the Company’s Registration Statement on Form S-8 (Registration No.
−Removed: Form of Non-U.S.
−Removed: Stock Option Grant Notice and Option Agreement for use under the Neurocrine Biosciences, Inc.
−Removed: 2025 Equity Incentive Plan
−Removed: Incorporated by reference to Exhibit 99.7 of the Company’s Registration Statement on Form S-8 (Registration No.
−Removed: Form of Non-U.S.
−Removed: Restricted Stock Unit Award Grant Notice and Restricted Stock Unit Award Agreement for use under the Neurocrine Biosciences, Inc.
−Removed: 2025 Equity Incentive Plan
−Removed: Incorporated by reference to Exhibit 99.8 of the Company’s Registration Statement on Form S-8 (Registration No.
−Removed: Amended and Restated Employment Agreement dated May 30, 2025 between the Company and Eiry W.
−Removed: Roberts, M.D.
−Removed: Incorporated by reference to Exhibit 10.1 of the Company's Current Report on Form 8-K filed on May 30, 2025
−Removed: Neurocrine Biosciences, Inc.
−Removed: 2018 Employee Stock Purchase Plan, as amended and restated
−Removed: Incorporated by reference to Exhibit 99.1 of the Company’s Registration Statement on Form S-8 (Registration No.
31.1 Description:
21 unchanged sentences
______________
−Removed: + Management contract or compensatory plan or arrangement.
* These certifications are being furnished solely to accompany this quarterly report pursuant to 18 U.S.C.
3 unchanged sentences
NEUROCRINE BIOSCIENCES, INC.
−Removed: July 30, 2025
+Added: October 28, 2025
/s/ Matthew C.
2 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.